Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07162246

Combined Gamma Knife/Linac Radiosurgery for Large Brain Tumors / Metastases

When cancer spreads to the brain, doctors often use a precise type of radiation therapy called stereotactic radiosurgery (SRS) to treat these tumors. This treatment can effectively control brain tumors while helping protect healthy brain tissue. However, when brain tumors or the areas where tumors were surgically removed are larger, treatment outcomes in terms of side effects and tumour control can become worse. Specifically, standard SRS on larger areas can have lower tumour control and higher risk of side effects, particularly a condition called radiation necrosis, which can cause swelling and damage in nearby healthy brain tissue.

Currently at Sunnybrook, large brain tumors are typically treated with SRS spread over 5 daily treatments using a machine called a linear accelerator. While this approach works well for many patients, it may be possible to improve results by combining two different types of radiation therapy machines - the linear accelerator and another specialized machine called the Gamma Knife.

In this study, the investigators want to test a new treatment approach where patients first receive 4 daily treatments using the linear accelerator, followed by a 1-2 week break, and then a final treatment using the Gamma Knife. The break between treatments allows the study doctors to take new scans and precisely target any remaining tumor, which may shrink during the break, thereby potentially reducing the amount of healthy brain tissue exposed to radiation. The Gamma Knife is also particularly good at delivering very precise radiation while sparing nearby healthy tissue. Lastly, there may be unique biological mechanisms between the two technologies that could be taken advantage of, by combining the technologies in the participant's treatment plan, to improve cancer control.

The investigators believe this combined approach might help achieve better tumor control while reducing the risk of side effects compared to using just the linear accelerator. This study will help the investigators understand if this new treatment strategy is safe and effective for patients with large brain tumors or surgical cavities, and whether it leads to better outcomes than the current treatment approach.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N3M5, Canada

Location status: Recruiting

Location contact

Aimee Theriault

CONTACT

[email protected]

4164806100 ext. x67364

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Presence of up to two large intracranial lesions
  • Up to 10 (previously untreated, or progressing after previous treatment) brain metastases at the time of enrollment on the diagnostic MRI (which includes the ILLs) to be treated with SRS/HSRS
  • Age => 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Expected survival >3 months
  • Patients that are deemed suitable for both GK and Linac based treatment
  • Patients that are able to hold systemic cancer chemotherapy/immunotherapy at least 2 days prior and following an SRS fraction

Exclusion criteria

  • Prior SRS to the ILLs
  • Prior WBRT, or plan for concurrent WBRT with the protocol treatment
  • Presence or history of any leptomeningeal/pachymeningeal disease
  • Metastatic disease within the ventricles of the brain or corpus callosum
  • Small cell, hematopoietic or germ cell primaries
  • Patient with absolutely contraindications for MRI
  • Severe symptoms that preclude MRI or treatment using standard procedures for Linac or GK
  • Pregnant or lactating patient
  • Inability or unwillingness to undergo informed consent or post-treatment follow-up

Treatment and study plan

radiation therapy

Radiation

Adaptive radiation therapy with GK boost

Primary outcomes

  1. Cumulative incidence of late local complication (LLC)

    Time frame: From end of protocol treatment to development of local failure or symptomatic ISRS Grade => 2 radionecrosis (assessed up to 24 months)

Secondary outcomes

  1. Overall Survival

    Time frame: Completion of protocol treatment to date of death (assessed up to 24 months)

  2. Distant Brain Progression-Free Survival

    Time frame: Date of protocol treatment to either appearance of additional metastatic disease within the brain, or death (assessed up to 24 months)

  3. Cumulative Incidence of Local Failure

    Time frame: Date of completion of protocol treatment to local failure (assessed up to 24 months)

  4. Cumulative Incidence of Radiation Necrosis

    Time frame: Date of protocol treatment to development of symptomatic radiation necrosis (assessed up to 24 months)

  5. Treatment-Related Toxicity

    Time frame: Throughout study participation and assessed up to 24 months following treatment completion

    From changes to baseline, as defined by CTCAE v5.0

  6. Change in Neurological Function

    Time frame: From enrollment onwards, up until 24 months after protocol treatment completion

    Through changes in the NANO scale

  7. Health-Related Quality of Life

    Time frame: From enrollment onwards, up until 24 months after protocol treatment completion

    Through changes in responses to health-related quality of life surveys completed during study participation

Study contacts

Contact information is provided by the study sponsor or research team.

Aimee Theriault

CONTACT

[email protected]

Hanbo Chan, MD

CONTACT

[email protected]

4164804974

Sponsors and collaborators

Lead sponsor

Sunnybrook Health Sciences Centre

Other

Registry information

Official study title

Combined Gamma Knife/Linac Hypofractionated Stereotactic Radiosurgery for Large Intracranial VolumEs (GK-LIVE): A Prospective Phase II Single-Arm Trial

Acronym: GK-LIVE

Important dates

Study start
2025
Primary completion
2029
Study completion
2030
First posted
Sep 9, 2025
Registry last updated
Sep 9, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.